Patient-Derived Xenograft/PDX Model Market

The global PDX model market in terms of revenue was estimated to be worth $426 million in 2023 and is poised to reach $839 million by 2028, growing at a CAGR of 14.5% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The key factors driving the growth of the global patient-derived xenografts model market are the growing demand for personalized medicine, technological advancements in PDX technology, and rising investments in cancer research. However, the FDA’s announcement to discontinue animal models for clinical trials is expected to restrain market growth to a certain extent.

Attractive Opportunities in the patient-derived xenografts/ PDX models market

To know about the assumptions considered for the study, Request for Free Sample Report

PDX Model Market Dynamics

DRIVER: Growing demand for personalized medicine

Personalized medicine aims to tailor medical treatments to individual patients based on their unique genetic and molecular profiles, enhancing treatment efficacy and minimizing adverse effects. PDX models have emerged as pivotal tools in this paradigm shift, providing a bridge between preclinical research and clinical application. PDX models allow researchers to replicate patient-specific tumors in an in vivo context, enabling the testing of various therapies for personalized treatment strategies. Their ability to maintain the heterogeneity and microenvironment of tumors closely mimics real-world patient scenarios. As a result, pharmaceutical companies and research institutions are increasingly adopting PDX models to develop and validate personalized treatment approaches.

RESTRAINT: FDA’s announcement to discontinue animal models for clinical trials

In December 2022, USFDA announced the dispensing of the prerequisite for animal testing in the initial phases of pharmaceutical development, marking a pivotal juncture in the regulatory framework governing drug research and innovation. This strategic shift stems from an amplified acknowledgment of the inherent limitations inherent in conventional animal models and the overarching drive to contemporize drug development paradigms. Although this shift is poised to herald constructive changes within the industry, it also holds the potential to engender certain challenges, particularly within the domain of the patient-derived xenograft (PDX) model market.

OPPORTUNITY: Emergence of CRISPR in biomedical research

CRISPR tool enables precise and efficient genetic modifications in PDX models, allowing researchers to create more accurate and sophisticated models that closely mimic human disease conditions. CRISPR-mediated modifications enable the introduction of specific mutations, deletions, or insertions into PDX models, replicating patient-specific genetic alterations observed in various diseases, including cancer. This capability not only enhances the authenticity of PDX models but also facilitates the investigation of genetic drivers and disease mechanisms. By utilizing CRISPR-edited PDX models, researchers can better dissect the role of specific genes and pathways in tumor growth, progression, and treatment responses, thereby providing valuable insights into personalized therapeutic strategies.

CHALLENGE: Development of alternative animal testing methods

Alternative methods, like in vitro cell culture models, organoids, and microphysiological systems, offer advantages such as reduced animal usage, cost-effectiveness, and high-throughput capabilities. This trend aligns with increasing ethical and regulatory concerns regarding traditional animal testing. As the pharmaceutical and research industries pivot toward more humane and predictive models, the adoption of these alternatives poses a potential threat to the demand for PDX models. Additionally, these alternatives offer faster results, allowing for quicker decision-making in drug development pipelines. This dynamic landscape necessitates strategic adaptations by PDX model providers to maintain their market relevance.

Patient Derived Xenograft / PDX Model Market Ecosystem:

Prominent companies in the market include well-established, financially stable manufacturers of patient-derived xenografts/ PDX model products. These companies have been operating in the market for several years and possess diversified, state-of-the-art technologies, product portfolios, and strong global sales and marketing networks. Prominent companies in this market include JSR Corporation (Japan), Wuxi Apptec (China), The Jackson Laboratory (US), Charles River Laboratories International, Inc. (US), Taconic Biosciences, Inc. (US), Oncodesign Precision Medicine (France), Inotiv, Inc. (US), Pharmatest Services (Finland), Hera BioLabs (US),  EPO Berlin-Buch GmbH (Germany), Xentech (France), Urosphere (France), Altogen Labs (US), Abnova Corporation (US), Genesis Biotechnology Group (US), Biocytogen Pharmaceuticals Co., Ltd. (China), Creative Animodel (US), BioDuro-Sundia (US), Aragen Life Sciences (India), Shanghai LIDE Biotech Co., Ltd. (China), Certis Oncology Solutions (US), InnoSer (Netherlands), IVRS AB (Sweden), Beijing IDMO Co. Ltd. (China), and Shanghai Chempartner Co. Ltd. (China).

The subcutaneous segment accounted for the largest share of the implantation method segment in the PDX Model Industry in 2023.

Based on implantation methods, the PDX model market is categorized into subcutaneous implantation, orthotopic implantation, and other implantation methods. In 2023, the subcutaneous segment accounted for the largest share and the fastest-growing segment of the patient-derived xenografts/ PDX models market. The major drivers are propelling the accessibility and ease of Implantation of the subcutaneous method and the cost and time efficiency of the method.

The pharmaceutical and biotechnology companies segment dominated the end-user segment in the PDX model industry in 2023.

Based on the end user, the segment of the PDX model market is categorized into pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions. In 2023, the pharmaceutical and biotechnology companies segment dominated the end-user segment with the highest revenue share. Collaborative projects amongst the pharmaceutical and biotechnology companies, rising numbers of drugs in the R&D pipeline, and increasing investment in R&D are propelling the growth of the pharmaceutical and biotechnology companies market.

North America was the largest market for PDX model industry in 2023.

Geographically, the PDX model market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East Africa. The patient-derived xenografts/ PDX models market is dominated by North America in 2023, and this dominance is anticipated to continue throughout the forecast period. Factors such as extensive research focusing on novel oncology therapies, a rise in cancer prevalence, and increased adoption of personalized medicine are driving the growth of the market in North America.

To know about the assumptions considered for the study, download the pdf brochure

The prominent players in the PDX model market are JSR Corporation (Japan), Wuxi Apptec (China), The Jackson Laboratory (US), Charles River Laboratories International, Inc. (US), Taconic Biosciences, Inc. (US), Oncodesign Precision Medicine (France), Inotiv, Inc. (US), Pharmatest Services (Finland), Hera BioLabs (US),  EPO Berlin-Buch GmbH (Germany), Xentech (France), Urosphere (France), Altogen Labs (US), Abnova Corporation (US), Genesis Biotechnology Group (US), Biocytogen Pharmaceuticals Co., Ltd. (China), Creative Animodel (US), BioDuro-Sundia (US), Aragen Life Sciences (India), Shanghai LIDE Biotech Co., Ltd. (China), Certis Oncology Solutions (US), InnoSer (Netherlands), IVRS AB (Sweden), Beijing IDMO Co. Ltd. (China), and Shanghai Chempartner Co. Ltd. (China).

Scope of the PDX Model Industry

This report categorizes the PDX model market to forecast revenue and analyze trends in each of the following submarkets:

By type

• Mouse Model
• Rat Model

By Implantation Method

• Subcutaneous implantation
• Orthotopic implantation
• Other implantation methods

By Tumor Type

• Gastrointestinal tumor models
• Gynecological tumor models
• Respiratory tumor models
• Urological tumor models
• Hematological tumor models
• Other tumor models

By Application

• Preclinical drug development
• Biomarker analysis
• Translational research
• Biobanking

By End Users

• Pharmaceutical & biotechnology companies
• Contract research organizations (CROs)
• Academic & research institutions

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia Pacific (APAC)
  • Japan
  • India
  • China
  • Australia
  • South Korea
  • Rest of Asia Pacific (RoAPAC)
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East Africa
  • Middle East
  • Africa

Recent Developments in PDX Model Industry

• In December 2022, Crown Bioscience, Inc., a subsidiary of JSR Life Sciences, entered into a worldwide licensing agreement with ERS Genomics Limited. This agreement granted Crown Bioscience complete global access to ERS's foundational CRISPR/Cas9 patent portfolio, enabling the company to utilize CRISPR/Cas9 for genetic editing on a global scale. Under the provisions of this agreement, Crown Bioscience broadened its capabilities in genetic manipulation. The company is exploring the potential of gene editing within three-dimensional models of patient-derived tumor organoids.
• In July 2022, GemPharmatech entered into a strategic licensing arrangement with Charles River Laboratories, Inc. This partnership entails the exclusive distribution rights for GemPharmatech's advanced NOD CRISPR Prkdc Il2r gamma (NCG) mouse lines within the North American region.
• In November 2021, Inotiv announced the completion of the acquisition of Envigo RMS Holding Corp., a leading global provider of research models and services.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst